

STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No.	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 2/Line 26	Abstract/Paragraph 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2-3/Line 26-45	Abstract/Paragraph 2-3
<b>Introduction</b>				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4-5/Line 65-104	Introduction/Paragraph 1-3
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5-6/Line 104-107	Introduction/Paragraph 3
<b>Methods</b>				
Study design	4	Present key elements of study design early in the paper	Page 6/Line 111	Methods/Paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6/Line 111-113	Methods/Paragraph 1
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <b><i>Cross-sectional study</i></b> —Give the eligibility criteria, and the sources and methods of selection of participants	Page 6 /Line 113-118; 137-139	Methods/Paragraph 1
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	N/A	N/A (This is a cross-sectional study)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 9/Line 178-186	Methods/Paragraph 7-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 7-9/Line 127-186	Methods/paragraph 2-8
Bias	9	Describe any efforts to address potential sources of bias	Page 9-10/Line 193-203	Methods/Paragraph 10-11
Study size	10	Explain how the study size was arrived at	Page 7/ Line 137-138	Methods/Paragraph 3
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 6/Line 120-126	Methods/Paragraph 1
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 9-10/Line 188-203	Methods/Paragraph 9-11

		(b) Describe any methods used to examine subgroups and interactions	Page 9-10/Line 197-199	Methods/Paragraph 10
		(c) Explain how missing data were addressed	N/A	N/A
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	Page 10/Line 193-199	Methods/Paragraph 10
		(e) Describe any sensitivity analyses	N/A	N/A
<b>Results</b>				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 6/Line 113-114; 118-120	Methods/Paragraph 1
		(b) Give reasons for non-participation at each stage	Page 6/Line 118-120	Methods/ Paragraph 1
		(c) Consider use of a flow diagram	N/A	Figure 1
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 10-11/Line 207-214	Results/ Paragraph 1
		(b) Indicate number of participants with missing data for each variable of interest	N/A	N/A
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	N/A	N/A
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	N/A	N/A
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	Page 11/Line 218-221; 227; 229-231	Results/ Paragraph 2-4
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 11/Line 211-214; 218-221	Results/ Paragraph 1-2
		(b) Report category boundaries when continuous variables were categorized	NA	NA
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 11/Line 221-225; Page 11-12/Line 231-232	Results/ Paragraph 2, 4
<b>Discussion</b>				

Key results	18	Summarise key results with reference to study objectives	Page 12/Line 244-251	Discussion/Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 16-17/Line 322-344	Discussion/Paragraph 6
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 12-16/Line 252-321	Discussion/Paragraph 2-5
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 13-16/Line 267-269; 304-305; 319-321	Discussion /paragraph 2-5
<b>Other information</b>				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 18/Line 358	Acknowledgments

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

Article information: <https://dx.doi.org/10.21037/qims-22-351>

\*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.